Community series in unleashing immunity against cancer: new horizons in immunotherapy: volume II

This Research Topic is the second volume of the “Unleashing Immunity against Cancer: New Horizons in Immunotherapy” Community Series. Please see Volume I here.From the approval of the first immune checkpoint inhibitors to the development of chimeric antigen receptor T cells, immunotherapy has demonstrated extraordinary potential to transform the landscape of cancer treatment. The ultimate goal is to develop novel agents or combination therapies that are consistently effective across most patients and cancer types, but there are ongoing challenges that hinder the achievement of this aim. Those include the inability to reverse the immunosuppressive microenvironment in certain tumors, where molecular pathways inhibit the activation and function of both innate or adaptive immune cells; the heterogeneity of tumor antigens; the lack of infiltrating immune cell populations in certain tumors; the toxicity associated with immune system overactivation; and the development of resistance mechanisms to immunotherapy, where tumors evade immune attacks through mechanisms like antigen loss or the recruitment of immunosuppressive cells. Addressing the ongoing challenges is crucial for improving the efficacy of immunotherapeutic strategies and for enhancing clinical success.This Research Topic aims to showcase the most recent advances to foster the exchange of ideas that push the boundaries of this promising field. Its objective is to gather high standard and novel contributions that will help gather in one place, research that will be used as a basis for future breakthroughs in cancer immunotherapy. An emphasis will be made on cross-disciplinary research (clinical and basic molecular biology, engineering and immunology, etc.), but this does not preclude contributions in immunology or cancer, that can be used in the future as a basis for cancer immunotherapy discoveries.This Research Topic seeks to bring together groundbreaking studies, original research, detailed descriptions or implementations of innovative techniques of significant interest, results from interventional studies on tailored therapies, robust bioinformatics analyses, and systematic or scoping reviews. Articles describing the use of artificial intelligence (AI) in the diagnosis and treatment with immunotherapy agents, such as Car-T, combination therapies immune checkpoints, etc., are welcome. The purpose is to compile evidence to better understand how tumor cells evade the immune system. Contributions should therefore focus on the interplay between the immune system and tumor cells, particularly their roles in tumor development and treatment responses.We welcome submissions exploring, but not limited to, the following themes:· Immune escape mechanisms within the tumor microenvironment and their implications.· The role of tumor and stromal compartments in shaping the response to immunotherapies.· Epigenetic mechanisms and extracellular vesicles involved in the interaction or communication between the immune system and the tumor.· Novel therapeutic strategies, such as immune checkpoint inhibitors, monoclonal antibodies, car-T cells, and/or oncolytic viruses, along with their mechanisms of action in antitumor immune responses.· Antigen processing and presentation.· Immunological tolerance, differentiation and function of T cells, and Natural Killer cell response against cancer.· Mechanisms of immunoglobulin gene diversification.· Homeostatic apoptotic cell clearance in cancer development and progression.· miRNAs, ncRNAs, and other novel RNAs playing critical roles in cancer by regulating gene expression, influencing tumor initiation, progression, and metastasis, as well as modulating the tumor immune microenvironment and resistance to immune therapies.· Involvement of AI in the diagnosis and treatment of cancer patients.Please also note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.Please also note that Prof. Tilman Sanchez-Elsner is currently employed by Catalysis SL. Topic editors: M. Teresa Agulló Ortuño, Tilman Sanchez-Elsner, Eva María Garrido-Martin Source: https://www.frontiersin.org/research-topics/85695/community-series-in-unleashing-immunity-against-cancer-new-horizons-in-immunotherapy-volume-ii